BioNTech Shares Under Pressure as Key Investor Exits
Published on 11/14/2025 at 14:20 | Redaktion boerse-global.de
The German biotech firm BioNTech finds itself navigating turbulent waters following a significant divestment by its longtime collaborator. In a decisive overnight move, Pfizer sold its entire remaining stake of 4.55 million American Depositary Receipts (ADRs), sending a stark signal to the market and contributing to a sharp pre-market decline in the share price.
Pfizer’s decision to liquidate its entire position marks a pivotal moment for BioNTech. The shares were offloaded via a block trade at prices ranging from $108 to $111.70 per ADR. This is more than a simple portfolio rebalancing; it is widely interpreted as a clear vote of no confidence from a former ally in the company’s near-term Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
